AMGN's Kyprolis Better Than Rival, KOOL Put On Notice, XON Inks Fruity Deal
Biologics Licensing Application for Opdivo for the treatment of patients with advanced squamous non-small cell lung cancer after prior therapy has been accepted for Priority Review by the FDA. The regulatory agency's decision on Opdivo is scheduled for ...
Nasdaq - Sun, 01 Mar 2015 22:45

Immunomedics (IMMU) Reports Data on Sacituzumab Govitecan in Lung Cancer
Immunomedics, Inc., (Nasdaq: IMMU) today announced that 33% of patients with small cell lung cancer (SCLC) and 31% with non-small cell lung cancer (NSCLC) had their tumor reduced in size by 30% or more, after being treated with sacituzumab govitecan ...
StreetInsider.com - Thu, 19 Feb 2015 11:30

MetaStat Ramps Up Validation Trials for 2016 Launch of Breast Cancer ...
However, the company believes MenaCalc has broader utility in all epithelial cancers, and has submitted an abstract for presentation at a medical conference at the end of April, which shows the test is prognostic in non-small cell lung cancer. MetaStat ...
GenomeWeb - Fri, 27 Feb 2015 10:26

Neutrophil-to-Lymphocyte Ratio Linked to mRCC Outcomes
Patients with metastatic renal cell carcinoma with an elevated neutrophil-to-lymphocyte ratio (NLR) at baseline had inferior outcomes compared with patients with a low NLR, showing that NLR may serve as an early biomarker of benefit of targeted therapy ...
Cancer Network - Mon, 02 Mar 2015 14:52

BioLineRx Announces Regulatory Submission for Phase 2b Trial for Novel AML ...
Pre-clinical studies show that BL-8040 inhibits the growth of various tumor types, including multiple myeloma, non-Hodgkin's lymphoma, leukemia, non-small cell lung carcinoma, neuroblastoma and melanoma. In these studies, BL-8040 significantly and ...
Rock Hill Herald (press release) - Mon, 02 Mar 2015 04:00

Mark Your Calendar For TCON, XLRN, Xenon Lights Up, MACK Gets Going
while presenting updated results from a phase II study of Sacituzumab govitecan, announced that 33% of patients with small cell lung cancer and 31% with non-small cell lung cancer had their tumor reduced in size by 30% or more. Including patients that ...
Nasdaq - Thu, 19 Feb 2015 20:41

Curis to Present at the 27th Annual Roth Conference
Curis, Inc. CRIS, +2.27% a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that Dr. Mani Mohindru, Vice President, Corporate Strategy and ...
MarketWatch - Tue, 03 Mar 2015 13:00

RECORDS: Births, deaths, bankruptcies
8. Jackson, Margaret; June 27, 1928, Evansville, end-stage Alzheimer dementia, Feb. 8. Jeffries, Linda Jean; Sept. 20, 1952, Evansville, metastatic small-cell lung cancer, Feb. 8. Julian, Mary Elaine; March 4, 1950, Evansville, metastatic breast cancer ...
Evansville Courier & Press - Sun, 01 Mar 2015 01:00


<-   1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014